HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced that Terry Rosen, Ph.D., Chief Executive Officer, will present
at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4,
2019 at 4 pm ET at the Grand Hyatt, in New York, NY.
To access the live audio webcast of the presentation, please visit the
“Investors” section of the Arcus website at www.arcusbio.com.
A replay of the webcast will be available for 30 days following the live
event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which is in a Phase 1/1b program to
evaluate AB928 in combination with other agents in multiple tumor types,
and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1
trial and is being tested in combination with Arcus’s other product
candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy
and in combination with AB122, and AB680, a small molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about Arcus
Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190521005716/en/
Katherine Bock
(415) 533-5670
kbock@arcusbio.com
Nicole Arndt
(510) 284-4728
narndt@arcusbio.com
Source: Arcus Biosciences, Inc.